

**PORTER WRIGHT MORRIS & ARTHUR<sub>LLP</sub>**  
Attorneys & Counselors at Law

Richard M. Mescher  
614-227-2026

41 South High Street  
Columbus, Ohio 43215-6194

Facsimile: 614-227-2100  
Toll Free: 800-533-2794

September 6, 2001

**VIA EXPRESS MAIL RECEIPT NO. EL 817538189US**

Box PCT  
Commissioner for Patents  
Washington, D.C. 20231

Re: First Inventor: James Allen  
Int'l App. No.: PCT/IB00/00205  
Filing Date: February 8, 2000  
Title: APPARATUS FOR DETERMINING WHEN A PATIENT IS  
SUSCEPTIBLE TO DEFIBRILLATION


Dear Sir:

Enclosed for filing, pursuant to U.S.C. 371, in connection with the above-identified international patent application are the following:

1. Petition for Revival of an International Application for Patent Designating the U.S. Abandoned Unintentionally Under 37 C.F.R. 1.137(b);
2. Copy of the International Application;
3. Preliminary Amendment to be entered prior to calculating claim fees;
4. International Search Report (EPA) including copies of references cited therein;
5. International Preliminary Examination Report;
6. Check No. 215950 in the amount of \$1,248.00 (S/E 1.17(m) petition fee: \$620, S/E national fee with EPO search report: \$430, S/E extra claims fee: 7 x \$9 = \$63, S/E multiple dependent claim fee: \$135);
7. Deposit Account Authorization (in duplicate); and
8. Certificate of filing by Express Mail.

The applicant claims small entity status. Also enclosed is a postcard receipt which we ask that you acknowledge and return to us.

Respectfully submitted,



Richard M. Mescher  
Reg. No. 38,242

Enclosures

Cincinnati • Cleveland • Columbus • Dayton • Naples, FL • Washington, DC  
www.porterwright.com

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors James Allen and Johnny Anderson

Title: "APPARATUS FOR DETERMINING WHEN A PATIENT IS  
SUSCEPTABLE TO DEFRIBRILLATION"

Int. Applic. No. PCT/IB00/00205

U.S. Serial No.: tbd

U.S. Filing Date: tbd

PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Please amend the above-identified application in the following manner prior to the examination thereof.

**IN THE CLAIMS:**

Please amend claims 6 and 7 in the following manner:

6. (amended) A defibrillator as claimed in claim 4, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

7. (amended) A defibrillator as claimed in claim 4, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

Please add new claims 8-11 in the following manner:

8. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

9. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is a

09/936001-02002

biphasic truncated exponential voltage.

10. (new) A defibrillator as claimed in claim 6, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

11. (new) A defibrillator as claimed in claim 8, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

### REMARKS

Claims 6 and 7 have been amended to remove multiple multiple-dependencies and new claims 8 to 11 have been added to incorporate the matter deleted from claims 6 and 7. Accordingly, claims 1 to 11 are currently pending in this application.

Enclosed herewith is a document containing marked-up versions of the changes made to the specification and claims by the current amendment. The document is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

In light of the foregoing, it is respectfully submitted that the present application is in a condition for allowance and notice to that effect is hereby requested. If it is found that that the present amendment does not place the application in a condition for allowance, applicant's undersigned attorney requests that the examiner initiate a telephone interview to expedite prosecution of the application.

If there are any fees resulting from this communication, please charge same to our Deposit Account No. 16-2326.

Respectfully submitted,

PORTER, WRIGHT, MORRIS & ARTHUR LLP



Richard M. Mescher, Reg. No. 38,242

Porter, Wright, Morris & Arthur  
41 South High Street  
Columbus, OH 43215-6194  
(614) 227-2026

September 6, 2001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

The Preliminary Amendment makes the following changes:

6. (amended) A defibrillator as claimed in claim 4 [or 5], wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

7. (amended) A defibrillator as claimed in claim 4, [5 or 6,] wherein the defibrillation voltage is a biphasic truncated exponential voltage.

8. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

9. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

10. (new) A defibrillator as claimed in claim 6, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

11. (new) A defibrillator as claimed in claim 8, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

APPARATUS FOR DETERMINING WHEN A PATIENT IS SUSCEPTIBLE  
TO DEFIBRILLATION

This invention relates to an apparatus for determining  
5 when a patient is susceptible to defibrillation.

Ventricular fibrillation (VF) is an abnormal rhythm of  
the heart which proves fatal if left untreated. The  
only effective treatment in an emergency situation is a  
10 high voltage shock applied to the heart either through  
electrodes applied to the chest wall or through  
electrodes attached directly onto the heart's surface.  
This high voltage shock attempts to interrupt the  
Ventricular fibrillation sequence and thereby restore  
15 the heart to a normal activation sequence.

A heart in VF is not effective and circulates very  
little blood, if any at all. A VF event is therefore  
probably the most time critical of all medical cases.  
20 With no blood circulation, brain tissue death or  
necrosis is imminent within minutes of the event  
occurring. The lack of blood supply to the body also  
compounds the time critical nature of the event because  
the heart itself requires blood supply via its coronary  
25 arteries in order to function efficiently. During VF  
with the blood supply to the whole body interrupted,  
the heart begins to experience ischaemia. Ischaemic  
heart tissue is more prone to VF than normal heart  
tissue. This means that as the VF rhythm persists, the  
30 ability to correct the sequence reduces and the risk of  
death increases.

There are various different mechanisms by which the

09936001-022002

Ventricular fibrillation sequence can maintain itself. Unlike Normal Sinus rhythm (a one shot sequence being actively initiated by the Sino-atrial Node), VF is a self sustaining closed loop sequence which is sometimes cyclic in nature but the nature of the sequence and its mechanism invariably changes over time. Furthermore, the mechanism by which any particular VF event is sustained will be related to the primary cause of the event. There are again various cardiac related abnormalities and trauma, which can promote a VF sequence in any human heart. These can be divided into two distinct groups, namely: Primary VF events and Secondary VF events.

Primary events are cases where the VF was an unexpected event. This can either be a sudden spontaneously initiated VF or a VF event due to some other sudden trauma or stress e.g. Acute Myocardial Infarction, Hypoxia, Lightning strike etc. Secondary events are those which occur although suddenly but predictably. These would include VF as a known risk of drug therapy and also patients who have a previous history of spontaneous VF events or rhythms which could promote VF. These two groups are managed differently by modern clinical response.

Secondary events are very well controlled by complex and miniaturised Implantable Cardiac Defibrillators (ICDs) which are surgically implanted within the chest and have electrodes directly connected to the heart. These devices continually monitor the hearts rhythm and deliver a shock to the heart if they detect the abnormal rhythm. Devices such as these have a very high

success rate for converting VF since they can respond very quickly.

Primary events however are not so easily controlled.

- 5 Due to the fact that by nature they are entirely unpredictable, they invariably occur outside hospital and therefore occur in the absence of specialised equipment and or qualified personnel. When they do occur, the response time may be long because an average
- 10 person will fail to recognise the seriousness of the condition. This means that the event can neither be quickly diagnosed nor effectively treated. The advent of the Portable Cardiac Defibrillator was a significant advance for emergency response teams allowing them
- 15 access to a very specialised medical instrument outside hospital. The procedure means that primary events can now be treated almost as successfully as secondary events provided the emergency response team can be despatched and reach the patient in time. This delay
- 20 could be further reduced if the use of Automatic External Defibrillators (AED's) becomes more widespread.

- Unfortunately, there is a dilemma associated with
- 25 external defibrillation. Unlike ICDs, external defibrillators apply the electrical shock across the thorax rather than directly across the heart, requiring much larger voltages in order to deliver the energy to the heart, necessary for termination of the VF rhythm.
- 30 As a result of this high voltage, very high currents can occur within the thoracic cage and cause significant damage to heart tissue. Clearly this is



undesirable and defeats the purpose of the intended treatment. Furthermore, external defibrillation is probabilistic at best. For instance, having established an energy setting which has produced a successful  
5 defibrillation in one instance and then attempting to defibrillate with the same or higher energy setting may fail. Of even further interest is the fact that a significantly lower energy setting can be successful, all within the same individual.

10 For these reasons, low energy defibrillation has been a goal for investigators for many years. The object of the invention discussed here is not however that of low energy defibrillation but rather one of providing a  
15 means by which the probability of any defibrillation attempt being successful can be increased. It will become clear later however, that increasing the probability can mean that fewer lower amplitude shocks are actually required to terminate any given VF rhythm.

20 Attempts to reduce the energy delivered to patients requiring defibrillation have evolved from recommended dose protocols, for example a first shock of 200J and if this is unsuccessful then a second shock of 200J and  
25 then repeated shocks of 360J until successful or the attempts are to be abandoned; to energy dose based upon patient characteristics, for example changing initial discharge voltage, initial current or the discharge pulse width in order to deliver less energy to patients  
30 with a lower Trans-Thoracic Impedance (TTI).

Although these types of refinement have advantages they do not increase the probability of defibrillation

success and they can also have serious disadvantages. For example while decreasing the width of a shock pulse and keeping the initial discharge voltage constant for a low impedance patient means the subject receives a lower energy dose, the initial current flow through the subjects torso (and heart) is actually much greater and therefore very damaging.

Present theory projects that the state of the myocardium at the exact instant the shock is applied is actually the determining factor of a successful defibrillation attempt. Experiments changing the shape of the shock pulse itself have shown that different pulse shape characteristics can change the amount of energy required to terminate VF. It is widely accepted that although VF has a random appearance, it is characteristic and can in fact be successfully modelled.

Investigations in this field have shown that the success of a defibrillation attempt is governed by the ability of the applied shock pulse and its shape to successfully organise a critical mass of myocardial cells. Specifically, the critical mass of cells must be placed into the refractory (or recovery) state. If a critical mass can be organised in this way, the heart essentially pauses. The normal sinus pacemaker can then initiate the heart's normal activation sequence and normality is restored.

Recently however, investigators have shown that during VF the heart's organisational state changes over time, and specifically that there are instants during any VF

- sequence at which the heart is in a more organisational state. Attempts by various investigators to identify these instants (called periods or instants of defibrillation susceptibility ) have only been
- 5 marginally successful. In 1988 Carlisle et al. synchronised the applied shock to the peaks, troughs and zero crossing points of the ECG during VF, without any significant success.
- 10 The object of the invention is therefore to provide a means for determining when a patient is susceptible to defibrillation whereby the probability of any defibrillation attempt being successful can be increased.
- 15 Accordingly, the invention provides an apparatus for determining when a patient is susceptible to defibrillation, the system comprising a plurality of electrodes for obtaining an electrocardiographic (ECG)
- 20 signal from a patient, and data processing means for (a) determining a region of the ECG signal where such signal passes from a first threshold to a second threshold at least equal in magnitude to that of the first threshold and of opposite polarity thereto while
- 25 the gradient of such signal remains within certain limits, (b) detecting the next following ECG signal peak, and (c) providing an output signal upon such detection.
- 30 The invention further provides defibrillation apparatus in which the occurrence of the output signal is used to trigger the application of a defibrillation voltage across the defibrillation electrodes.

09936001-022003

In such case the electrodes providing the ECG signal may be the defibrillation electrodes themselves.

- 5 The first and second thresholds and gradient limits may be calculated automatically from measured parameters of the preceding ECG signal, or they may be empirically determined constant values.
- 10 In the embodiment to be described the data processing means is implemented in digital circuitry. However, it may alternatively be implemented in analog circuitry or a combination of analog and digital circuitry.
- 15 An embodiment of the invention will now be described, by way of example, with reference to the accompanying drawings, in which:
- 20 Fig. 1 shows a single bipolar lead ECG showing a normal sinus beat measured from the body surface,
- Fig. 2 is a diagram of a heart showing average cardiac vectors at four instants during a normal sinus beat corresponding to the ECG in Fig. 1,
- 25 Fig. 3 shows normal sinus rhythm,
- Fig. 4 shows normal depolarisation and repolarisation of an isolated section of myocardium,
- 30 Fig. 5 is a typical bipolar ECG trace showing VF,
- Fig. 6 shows a possible activation mechanism generating

09936001-022003

a VF ECG trace,

Fig. 7 shows a single re-entrant activation loop,

5 Fig. 8 shows the VF epoch of Fig. 5 with time markers showing the defibrillation points identified by the prior art,

Fig. 9 illustrates the detection constraints imposed  
10 by the invention,

Fig. 10 shows the VF epoch of Fig. 5 with time markers showing the points identified by the invention,

15 Fig. 11 shows defibrillation apparatus embodying the invention,

Fig. 12 is a functional block diagram of the internal circuitry of the apparatus of Fig. 11,  
20

Fig. 13 is a flow diagram of the operation of the shock point detector of Fig. 12,

Fig. 14 is an example of the use of the invention to  
25 terminate a VF sequence through delivery of a biphasic electrical shock, and

Fig. 15 is an example of the use of the invention terminating multiple re-entrant loops to form a  
30 dominant re-entrant loop.

The invention is based on the theory that the instants of susceptibility can be detected and quantified by the

09936004 022000

average cardiac vector but that the amplitude and velocity of the approaching dominant wavefront is insufficient to accurately determine the instant of susceptibility. The instantaneous direction of the dominant wavefront and the nature of the myocardial organisation responsible for this direction is crucial to identifying the exact instant of susceptibility.

Fig. 1 shows an ECG obtained from a heart in normal sinus rhythm. Fig. 2 shows a diagrammatic sketch of the heart with the average cardiac depolarisation vectors superimposed. Each vector is called an average vector because it depicts the sum of all the myocardial cells activated at that particular point in time. The vectors are numerically labelled to portray the time sequence and can be related to the ECG trace Fig. 1 in order to appreciate the myocardial organisation at any given time instant. Note that the placement of the electrodes e1 and e2 shown in Fig. 2 (which in this case are the defibrillation electrodes ultimately used to shock the heart) determines the shape of the acquired ECG so the organisational state of the heart at any given time instant as determined by any given ECG lead is with reference to the direction resolved by that particular lead. Note also that normal Sinus rhythm is a very stable sequence repeated in a controlled manner by the heart, Fig. 3 shows an example ECG lead trace for reference.

Further considering Fig. 1, it can be appreciated that as the heart activates the average cardiac vector changes position from that denoted by  $t_1$  to  $t_2$  then to  $t_3$  and finally to  $t_4$ . Of particular interest here is

that the ECG traces achieves maximum positive deflection between time instants  $t_2$  and  $t_3$ . Referring now to Fig. 2 we see that between  $t_2$  and  $t_3$  the vector would be pointing in the direction of the axis between the two electrodes  $e_1$  and  $e_2$ . It is a fundamental property of any bipolar ECG lead that when a depolarising myocardial wavefront is approaching along the axis of the lead, a maximum (positive) deflection will be measured and when it is retreating along the axis of the lead, a minimum (negative) deflection will be measured. Furthermore, if the wavefront is travelling in a direction perpendicular to the lead axis, no deflection (zero potential difference) will be measured. Before considering the properties of a VF sequence it must be appreciated that the ECG trace and the average cardiac vectors are a consequence of the activation wavefronts.

Fig. 4 shows how the activation of an isolated section of myocardium can be used to demonstrate a normal depolarisation and repolarisation sequence. Note that the average vectors are differentiated by a "- sign" for the depolarisation wave and a "+ sign" for the repolarisation wave. Above the tissue section we can also see the electrical trace which this isolated activation would produce measured from the two electrodes positioned either side of the section. The measured ECG trace shows the sharper, faster depolarisation wave inscribing a positive deflection as it approaches the positive electrode, this is then followed by the slower repolarisation wave which inscribes a negative deflection. The repolarisation wave is negative because it is of the opposite polarity

(positive rather than negative) as it approaches the positive electrode.

- This particular activation sequence (with the repolarisation wave following behind the initial depolarisation wave) is typical of atrial tissue. Ventricular tissue actually repolarises in the opposite direction to which it initially depolarises. In terms of the measured ECG and Fig. 4 the only difference would be that for ventricular tissue, since the repolarisation wave would be receding away from the positive electrode it would actually inscribe a positive deflection in the ECG trace.
- Now let us consider a VF trace and how myocardial tissue generates such a trace. Fig. 5 shows a typical epoch of VF. As we can see the trace does indeed appear random. This sequence is generated by tissue containing a varying number of wavefronts. Fig. 6 shows one possibility. Here we see that there are several wavefronts circulating without any apparent stimulus. These "loops" are self sustaining because the tissue is repolarising abnormally quickly so that the depolarising wavefront can actually reactivate the tissue rather than allowing the tissue to pause and wait for a normal stimulus. Note that since the individual wavefronts are completely independent, they will interfere so that the overall activation vector changes with time as presented by the ECG trace.
- Furthermore, in this particular example the "loops" are all the same diameter, this however would not necessarily be the case. It must now be appreciated



that at any given time instant the wavefronts can be seen to be adding together more than at other times, resulting in a higher amplitude activation vector being measured externally. At other times the wavefronts  
5 could interfere more destructively causing lower amplitude activation vectors to be measured.

Fig. 7 shows another possibility. Here only one large wavefront is shown circulating around the entire tissue  
10 section. The nature of this particular tissue activation pattern is the most fundamental type of self-sustaining "or re-entrant" activation. This more basic type of abnormal activation is more descriptive of a Ventricular Tachycardia sequence. Note that as  
15 this single wavefront rotates, at any time instant there are large areas of the tissue section which be can be noted as either depolarised or repolarised. In fact at any time instant there will be almost one half of the tissue section depolarised and one half  
20 repolarised. If we now deliver an electric shock at a random time instant to the tissue section, it is clear why such a shock may only sometimes be successful. At the instant the shock is applied, the areas of tissue that are depolarised will be unaffected, the areas that  
25 are repolarised (and therefore ready for activation) will begin to depolarise. Since these areas are depolarised earlier as a result of the shock stimulus, they cannot now be activated again by the already present circulating wavefront. The activation sequence  
30 is therefore terminated by interruption of the re-entrant loop. Note therefore that to successfully terminate such an abnormal sequence, the electrical

0936001 02200

shock should be delivered at any time instant where the result of the shock would be to cause a significant amount of the tissue mass to be depolarised so as to interrupt the abnormal sequence. This implies that the electrical shock should be applied at any time instant where there is a significant amount of the tissue mass in a state of repolarisation.

If we now return to Fig. 6 and consider again how these individually circulating wavefronts interfere with each other over time, then we can see that the average cardiac vector and it's measurement (the ECG trace) is generated by the activation wavefronts combined. Note also that the act of measuring a threshold or a gradient at that threshold is not sufficient to determine the activation state of the tissue. Since the amplitude of the ECG trace is due to both the mass of tissue activation together with the direction in which it is activating they cannot be separated by a threshold. Furthermore the gradient only reveals the speed at which the overall wavefront is approaching or receding.

Fig. 8 shows time instant markers positioned at points along the trace of Fig. 5 where the prior art suggests susceptibility for defibrillation. It is the purpose of this invention to identify the optimum instant for susceptibility for interruption of a re-entrant loop by using the ECG trace to determine both from which direction the overall wavefront is coming and also in which direction it is going. This is achieved by noting a peak average cardiac vector of significant amplitude

and then detecting an amplitude of like magnitude but of opposite polarity immediately following the first noted peak. Furthermore the form of the ECG trace between these instants of opposite polarity must be appreciably linear (that is to say of relatively uniform gradient). The average cardiac vector presents this property when the overall activation is due to a significantly sized activation wavefront travelling away from a point far from the positive sensing electrode to a point near to the same electrode. Upon detection of a wavefront with this property at the positive electrode, there will be a significant mass of tissue having just been depolarised and therefore emerging from recovery ready for activation. Note also that this tissue mass will have been travelling in a direction towards the positive electrode, meaning that the intracellular current flow within the tissue will also be directed in that direction. The defibrillating shock should therefore be delivered immediately upon detection of this instant so that the sequence can be successfully interrupted.

Furthermore it is crucial that the polarity of the defibrillation shock is such that the critical mass of cells are depolarised and that the shock is not applied across the tissue in a direction attempting to reverse repolarisation. A reverse polarity shock would require more energy since it would have to both reverse repolarisation and then depolarise the critical mass, a process which is very unlikely since having attempted to reverse repolarisation, the critical mass of cells will be less likely to depolarise properly and the VF

sequence would simply persist.

Thus, as shown in Fig. 9 for a negative-to-positive-going portion of the ECG signal, the object of the invention is to identify a region of the ECG signal where the signal passes from a negative threshold "-th" of significant magnitude to a positive threshold "+th" at least equal in magnitude to the negative threshold, while the gradient of the signal remains within certain limits. In Fig.9, provided the signal stays within the "channel" defined by the notional inclined parallel dotted lines separated by the horizontal distance  $\delta\alpha$ , it is assumed that the gradient has remained within the required limits. Having detected such a region of the ECG signal, the optimum point for defibrillation is at the next following ECG signal peak, i.e. local maximum, at which the defibrillation shock should be delivered.

The invention is equally applicable to positive-to-negative-going portions of the ECG signal, in which case one would detect a region of the ECG signal where the signal passes from a positive threshold of significant magnitude to a negative threshold at least equal in magnitude to the positive threshold, while the gradient of the signal remains within certain limits, and the optimum point for defibrillation would be at the next following local minimum of the ECG signal.

Fig. 10 shows the previous epoch of VF from Fig. 5 but here the above technique has identified only the instants  $tn1$  and  $tn2$  which were truly susceptible to defibrillation. As mentioned previously, the upper and lower thresholds, indicated in Fig. 10 by the

horizontal dashed lines, and the gradient limits may be calculated automatically from measured parameters of the preceding ECG signal, or they may be empirically determined constant values. In the case of Fig. 10 the thresholds are assumed to be a function of the average peak value of the preceding ECG signal.

An embodiment of the invention is shown in Figs. 11 to 13 and is based upon a known type of external defibrillation apparatus. Since the modifications necessary to embody the invention are internal, the apparatus has the outward appearance (Fig. 11) of a conventional external defibrillation apparatus.

Thus the apparatus includes a defibrillation unit 10 and a pair of defibrillation electrodes 12, 14 for application to a human torso 16, the electrodes being plugged into the unit 10. As well as being used to provide a defibrillation shock, the electrodes 12, 14 are also used as ECG electrodes to produce an ECG signal in known manner which is displayed on an ECG monitor 18 in the unit 10. A gain control knob 20 allows the amplitude of the signal trace to be adjusted on the monitor 18. The unit 16 also includes a rotary dial 22 to select the energy of the defibrillation shock to be applied to the patient, and a push button 24 which when pressed causes a capacitor inside the unit 16 to charge to a voltage determined by the setting of the selector 22. Finally, a further push button 26 is provided. In the conventional defibrillator an operator pushes this button to cause the capacitor to discharge through the electrodes 10, 12 to deliver a shock to the patient. However, in the

present case the internal circuitry of the unit 16 is modified so that pushing the button 26 merely enables a shock to be given, the actual timing of the shock being determined according to the principles discussed above  
5 with reference to Fig. 9.

Fig. 12 is a block diagram of internal circuitry of the unit 10. The individual blocks shown in Fig. 12 identify the main functions of the unit, and do not  
10 necessarily constitute separate and distinct parts of the circuitry.

Signal Conditioning and Amplification circuit 30 receives the signals from the individual defibrillation  
15 electrodes 12, 14 and generates therefrom in known manner the ECG signal for display on the monitor 18. Energy Select circuit 32 is responsive to the setting of the rotary dial 22 to establish the selected energy level and, when the push button 24 is pressed, Charge  
20 circuit 34 charges the capacitor to a level corresponding to the selected energy level.

In the prior art, and as indicated by the dashed line, Shock Enable circuit 36 is directly responsive to the  
25 operator pressing the push button 26 to provide an input to Shock Delivery circuit 38, causing the latter to immediately discharge the capacitor through the electrodes 12, 14 to deliver a defibrillation shock to the patient. However, in the present embodiment the  
30 Shock Enable circuit 36 provides instead an input to Trigger Shock circuit 40 interposed between circuits 36 and 38. The Trigger Shock circuit 40 also receives an input from Shock Point Detector circuit 42 which is

responsive to the ECG signal from circuit 30 to detect  
instants susceptible to defibrillation according to the  
principles of Fig. 9. The Shock Point Detector circuit  
42 provides the said input to circuit 40 when such an  
5 instant is detected.

The Trigger Shock circuit 40 is essentially an AND  
circuit and, when it receives an input simultaneously  
from both circuits 36 and 42, it provides an input to  
10 the Shock Delivery Circuit 38 which causes the latter  
to immediately discharge the capacitor through the  
electrodes 12, 14 to deliver a defibrillation shock to  
the patient. Thus, as compared to the conventional  
external defibrillator which provides a defibrillation  
15 shock immediately the button 26 is pressed, which can  
occur at any arbitrary point during the ECG cycle due  
to the rapid changes in the signal and the relatively  
slow reaction of the human operator, in the present  
apparatus when the button 26 is pressed the apparatus  
20 waits until the Shock Point Detector circuit 42  
identifies an instant susceptible to defibrillation and  
only then administers the shock. Such instant will  
typically occur a fraction of a second after the button  
26 is pressed, and thus the button 26 must be held down  
25 until the shock is given. Optionally, if no suitable  
instant is detected within a predetermined time, say  
about two seconds, after the button 26 is pressed, the  
apparatus may be designed to administer a shock at that  
point anyway. The shock is preferably an n-phasic  
30 truncated exponential shock where n is greater than  
one. That is to say, it consists of several truncated  
exponential voltage pulses of alternating polarity. In  
particular it may be a biphasic truncated exponential

shock.

The implementation of circuits 30 to 38 is well known in the art and does not need further description.

5 Also, circuit 40 is essentially an AND circuit and is readily implemented by those skilled in the art. The function of the Shock Point Detector circuit 42 is performed in this embodiment by a suitably programmed microprocessor. In order to allow the microprocessor  
10 to process the ECG signal an analog-to-digital (A/D) converter (not shown) is used to convert the analog ECG signal to digital form.

Fig. 13 is a flow diagram of the program which is run  
15 on the microprocessor to identify the instants susceptible to defibrillation. The program starts when the push button 26 is pressed. Step 50 repeatedly tests the ECG signal to detect the ECG signal crossing a predetermined negative threshold in a positive-going  
20 direction, and when such a crossing is detected step 52 analyses the signal to determine its instantaneous gradient. Step 54 tests the gradient thus determined for being within predetermined limits. If the gradient is not within the limits, control passes back to step  
25 50. If it is within limits, step 56 tests to determine if the signal has crossed a predetermined positive threshold at least equal in magnitude to that of the negative threshold. If it has, step 58 detects the next following peak (local maximum) and step 60  
30 provides an output to the Trigger Shock circuit 40. If, however, step 56 determines that the signal has not crossed the positive threshold, control returns to step 52 and steps 52 to 56 are run through again. Thus, as

09335001.022002



time progresses from the crossing detection at step 50 the program repeatedly tests the gradient for being within limits, until either the signal crosses the positive threshold, in which case the next following  
5 peak is detected, or the gradient falls outside the limits, in which case control reverts to step 50 to look for the next crossing of the negative threshold.

Fig. 14 shows the invention having identified the  
10 correct instant of susceptibility and a biphasic truncated exponential shock was delivered to successfully terminate the VF event. The invention can also be used to terminate VF sequences sustained by multiple re-entrant loops as described above and shown  
15 in Fig. 6. In this instance the invention identifies the instant of greatest susceptibility and a first shock is delivered. Fig. 15 shows this process. As the figure shows, the purpose of the first shock is not to activate a critical mass and thereby terminate the VF  
20 sequence, but rather to just merge some of the small loops into one bigger loop. Successive shocks can therefore merge the loops into bigger and bigger loops until a final shock terminates the VF sequence.

25 The invention has been used to identify the instant of susceptibility in each case. This means that the energy required to defibrillate (either single shock or through multiple sequential shocks) is considerably less than would be required to activate a critical mass  
30 at a time instant that is not susceptible.

Although the above embodiment has used the same electrodes for both defibrillation and to provide the

09936001.022002

ECG signal which is analysed to determine the instant of susceptibility to defibrillation, the ECG signal could alternatively be derived from separate electrodes.

5

Also, although the foregoing has described the invention in the context of an external defibrillator, i.e. where the electrodes are connected externally to the patient's body, it will be clear to those skilled in the art that the invention may be used to determine the instant of susceptibility to defibrillation in the case of implanted electrodes which are connected directly to the heart's surface.

10

15 The invention is not limited to the embodiments described herein which may be modified or varied without departing from the scope of the invention.

09935004 022003

## CLAIMS

1. An apparatus for determining when a patient is susceptible to defibrillation, the system comprising a plurality of electrodes for obtaining an electrocardiographic (ECG) signal from a patient, and data processing means for (a) determining a region of the ECG signal where such signal passes from a first threshold to a second threshold at least equal in magnitude to that of the first threshold and of opposite polarity thereto while the gradient of such signal remains within certain limits, (b) detecting the next following ECG signal peak, and (c) providing an output signal upon such detection.
2. An apparatus as claimed in claim 1, wherein the first threshold is a negative threshold and the second threshold is a positive threshold.
3. An apparatus as claimed in claim 1, wherein the first threshold is a positive threshold and the second threshold is a negative threshold.
4. A defibrillator including an apparatus as claimed in claim 1, 2 or 3 wherein the occurrence of the output signal is used to trigger the application of a defibrillation voltage across defibrillation electrodes.
5. A defibrillator as claimed in claim 4, wherein the electrodes providing the ECG signal are also the defibrillation electrodes.

6. A defibrillator as claimed in claim 4 or 5, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

5

7. A defibrillator as claimed in claim 4, 5 or 6, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

0935001-02200




Fig.1




Fig.2

200220\* T009E660




Fig.3





Fig.4





**Fig. 5**

09/936001 02000




Fig.6




Fig.7

09/936001 PCT/IB00/00205




Fig.8

200220 10093660




Fig.9

10/15





Fig.10


200220 10093660

FIG. 11



12/15

Fig 12








FIG. 13.




Fig.14




Fig.15

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My citizenship, residency, and mailing address are as identified below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed therein and for which a patent is sought on the invention entitled

"APPARATUS FOR DETERMINING WHEN A PATIENT IS SUSCEPTIBLE TO DEFIBRILLATION";

the specification of which was filed on 02/08/2000 (MM/DD/YYYY) as PCT International Application Number PCT/IB00/00205 and was amended by Preliminary Amendment filed to the USPTO on 09/06/01 (MM/DD/YYYY).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d), or 365(b) of any foreign application(s) for patent or inventor's certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

<u>Country</u>	<u>Prior Foreign Application No.</u>	<u>Foreign Filing Date (MM/DD/YYYY)</u>	<u>Priority Claimed?</u>	<u>Certified Copy Attached?</u>
Ireland	S990090	02/08/1999	Yes	No

I hereby designate the following as my mailing address:

**Porter, Wright, Morris & Arthur LLP**  
ATTN: Intellectual Property Department  
41 South High Street, 28th Floor  
Columbus, Ohio 43215-6194

I hereby request that all telephone calls be directed to: Richard M. Mescher at (614) 227-2026

I hereby appoint each of the following as my attorneys, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Edwin M. Baranowski, Reg. No. 27,482;  
Laurie N. Jacques, Reg. No. 35,905; and  
Richard M. Mescher, Reg. No. 38,242.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, Section 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Inventor: JAMES ALLEN  
Citizenship: Great Britain  
Inventor's Signature: [Signature]  
Date Signed: 24<sup>th</sup> JAN 2002.

Residence: Muckamore, Great Britain  
Mailing Address: 10 Dunadry Road  
Muckamore, County Antrim  
BT15 4SQ GREAT BRITAIN

MUCKAMORE STABLES  
55 BALLYMARTIN RD  
TEMPLEPATRICK  
BALLYCHARE CO ANTRIM  
BT39 0BS GREAT BRITAIN.

GBX

(2) Inventor: JOHNNY HOUSTON ANDERSON  
Citizenship: Great Britain  
Inventor's Signature: J. Anderson  
Date Signed: 24<sup>th</sup> JAN 2002.

Residence: Hollywood, Great Britain  
Mailing Address: 16 Torgrange  
Hollywood, County Down  
BT18 0NG GREAT BRITAIN

58 ARDMORE ROAD  
HOLLYWOOD  
CO. DOWNS  
N. IRELAND IEY  
BT18 0PJ